Laura L. Dickey

Laura L. Dickey

Auto-generated profile, based on publicly available information

Laura L. Dickey

Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in eLife
Verified
Journal Article
Open access
DBD Garrett Brown
D Garrett Brown
RSRaymond Soto
Raymond Soto
SYSoumya Yandamuri
Soumya Yandamuri
CSColleen Stone
Colleen Stone
LDLaura Dickey
Laura Dickey
JRJune L Round
June L Round
Symbiotic microbes impact the function and development of the central nervous system (CNS); however, little is known about the contribution of the microbiota during viral-induced neurologic damage. We identify that commensals aid in host defense following infection with a neurotropic virus through enhancing microglia function. Germfree mice or animals that receive antibiotics are unable to control viral replication within the brain leading to increased paralysis. Microglia derived from germfree or antibiotic-treated animals cannot stimulate viral-specific immunity and microglia depletion leads to worsened demyelination. Oral administration of toll-like receptor (TLR) ligands to virally infected germfree mice limits neurologic damage. Homeostatic activation of microglia is dependent on intrinsic signaling through TLR4, as disruption of TLR4 within microglia, but not the entire CNS (excluding microglia), leads to increased viral-induced clinical disease. This work demonstrates that gut immune-stimulatory products can influence microglia function to prevent CNS damage following viral infection.

7 September 2016 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
LDLaura L. Dickey
Laura L. Dickey
CWColleen L. Worne
Colleen L. Worne
JGJessica L. Glover
Jessica L. Glover
TLThomas E. Lane
Thomas E. Lane
RORyan M. O'Connell
Ryan M. O'Connell
MicroRNAs (miRNAs) are noncoding RNAs that modulate cellular gene expression, primarily at the post-transcriptional level. We sought to examine the functional role of miR-155 in a model of viral-induced neuroinflammation. Acute encephalomyelitis and immune-mediated demyelination were induced by intracranial injection with the neurotropic JHM strain of mouse hepatitis virus (JHMV) into C57BL/6 miR-155 +/+ wildtype (WT) mice or miR-155 −/− mice. Morbidity and mortality, viral load and immune cell accumulation in the CNS, and spinal cord demyelination were assessed at defined points post-infection. T cells harvested from infected mice were used to examine cytolytic activity, cytokine activity, and expression of certain chemokine receptors. To determine the impact of miR-155 on trafficking, T cells from infected WT or miR-155 −/− mice were adoptively transferred into RAG1 −/− mice, and T cell accumulation into the CNS was assessed using flow cytometry. Statistical significance was determined using the Mantel-Cox log-rank test or Student’s T tests. Compared to WT mice, JHMV-infected miR-155 −/− mice developed exacerbated disease concomitant with increased morbidity/mortality and an inability to control viral replication within the CNS. In corroboration with increased susceptibility to disease, miR-155 −/− mice had diminished CD8+ T cell responses in terms of numbers, cytolytic activity, IFN-γ secretion, and homing to the CNS that corresponded with reduced expression of the chemokine receptor CXCR3. Both IFN-γ secretion and trafficking were impaired in miR-155 −/− , virus-specific CD4+ T cells; however, expression of the chemokine homing receptors analyzed on CD4+ cells was not affected. Except for very early during infection, there were not significant differences in macrophage infiltration into the CNS between WT and miR-155 −/− JHMV-infected mice, and the severity of demyelination was similar at 14 days p.i. between WT and miR-155 −/− JHMV-infected mice. These findings support a novel role for miR-155 in host defense in a model of viral-induced encephalomyelitis. Specifically, miR-155 enhances antiviral T cell responses including cytokine secretion, cytolytic activity, and homing to the CNS in response to viral infection. Further, miR-155 can play either a host-protective or host-damaging role during neuroinflammation depending on the disease trigger.

1 July 2017 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
LDLaura L. Dickey
Laura L. Dickey
THTimothy Michael Hanley
Timothy Michael Hanley
THThomas B. Huffaker
Thomas B. Huffaker
ARAndrew G. Ramstead
Andrew G. Ramstead
RORyan M. O'Connell
Ryan M. O'Connell
TLThomas E. Lane
Thomas E. Lane

15 September 2019 in Journal of Virology
Verified
Journal Article
Open access
PDF file
BMBrett S Marro
Brett S Marro
DSDominic Skinner
Dominic Skinner
YCYuting Cheng
Yuting Cheng
JGJonathan J Grist
Jonathan J Grist
LDLaura L Dickey
Laura L Dickey
TLThomas E. Lane
Thomas E. Lane
Signaling through the chemokine receptor CXCR2 in oligodendroglia is important for developmental myelination in rodents, while chemical inhibition or nonspecific genetic deletion of CXCR2 appears to augment myelin repair in animal models of the human demyelinating disease multiple sclerosis (MS). To better understand the biology of CXCR2 signaling on oligodendroglia, we generated transgenic mice in whichCxcr2is selectively ablated in oligodendroglia upon treatment with tamoxifen. Using a viral model of neuroinflammation and demyelination, we demonstrate that genetic silencing of CXCR2 on oligodendroglia did not affect clinical disease, neuroinflammation, or demyelination, yet there was increased remyelination. These findings support and extend previous findings suggesting that targeting CXCR2 may offer a therapeutic avenue for enhancing remyelination in patients with demyelinating diseases.

3 July 2019 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
HKHeejoo Kim
Heejoo Kim
LDLaura Dickey
Laura Dickey
CSColleen Stone
Colleen Stone
JJJillian L. Jafek
Jillian L. Jafek
TLThomas E. Lane
Thomas E. Lane
DTDean Tantin
Dean Tantin
Treatments for autoimmune diseases aim to dampen autoreactivity while preserving normal immune function. In CD4+ T cells, the transcription factor Oct1/Pou2f1 is a dispensable transcription factor for T cell development and response to primary infection, but promotes expression of target genes, including Il2 and Ifng, under conditions of antigen reencounter. As a result, they are more strongly expressed upon secondary stimulation. Such repeated antigen encounters occur in memory recall responses, in autoimmunity where self-antigen can be recognized multiple times, and in chronic infection where foreign antigen is persistent. Based on these previous findings, we hypothesized that Oct1 loss would protect animals from autoimmunity but maintain normal responses to pathogens in the CNS. We used a conditional mouse Oct1 (Pou2f1) allele and a CD4-Cre driver to determine the effect of T cell-specific Oct1 loss on autoimmune- and viral-induced neuroinflammation using an autoantigen-driven EAE model of autoimmunity and a JHMV model of viral infection. Oct1 conditional deletion mitigated clinical scores and reduced infiltrating T cells and cytokine production in the EAE model. Consistently, Oct1-deficient CD4+ T cells stimulated in vitro showed increased expression of markers associated with T cell anergy, particularly in the absence of co-stimulatory signals. In contrast, anti-viral T cell effector functions are intact in the absence of Oct1, with no changes in neuroinflammation, infiltrating T cells or cytokine production. Our findings uncover a significant difference between the effect of Oct1 loss on autoimmune and anti-pathogen responses, which potentially could be exploited for therapeutic benefit.